What is claimed is:

1. Use of levodopa in the manufacture of a medicament ~~A method~~ for treating ~~a patient diagnosed with~~ Parkinson's disease in a levodopa naïve patient, wherein the medicament is to be orally administered in ~~comprising the oral administration of~~ a controlled release dosage form comprising levodopa and ~~a controlled release excipient and/or~~ a muco-adhesive excipient~~;~~, wherein the muco-adhesive excipient is a methacrylate copolymer, and wherein ~~the administration of~~ the controlled release dosage form is to be administered twice a day with each dose comprising 140 mg of levodopa and ~~occurs every twelve hours wherein the~~ a total daily ~~dose is of~~ levodopa dose of 280 mg~~provided by the controlled release dosage form is about 400 mg to about 1,400 mg; the dose of levodopa administered every twelve hours from the controlled release dosage form is about 200 mg to about 700 mg and the patient prior to receiving the controlled release dosage form of levodopa was being treated with a total daily dose of 500 mg or less of levodopa administered in three, four or more doses in a twenty-four hour period~~.

~~2. The method of claim 1 wherein the dose of levodopa administered every twelve hours from the controlled release dosage form is about 200 mg to about 500 mg.~~

~~3. The method of claim 1 wherein the dose of levodopa administered every twelve hours from the controlled release dosage form is about 250 mg to about 450 mg.~~

2~~4~~. The use ~~method~~ of claim 1, wherein the controlled release dosage form further comprises carbidopa or an ester or a salt thereof.

3~~5~~. The use ~~method~~ of claim 1~~4~~, wherein the controlled release dosage form comprises one or more capsules comprising~~:~~

~~(a)~~ 140 mg of levodopa and 35 mg of carbidopa~~;~~

~~(b) 210 mg of levodopa and 52.5 mg of carbidopa;~~

~~(c) 280 mg of levodopa and 70 mg of carbidopa;~~

~~(d) 350 mg of levodopa and 87.5 mg of carbidopa; or~~

~~(e) a combination of the foregoing~~.

46. The use ~~method~~ of claim 1, wherein the controlled release dosage form when tested using a USP Apparatus I at 75 rpms and 37°±0.5°C with 500-900 ml of simulated gastric fluid (pH 1, without enzyme) for 2 hours and pH 6.8 phosphate buffer thereafter exhibits the following ~~levodopa~~ release profile for the levodopa:

20% to 60% of levodopa is released after 2 hours;

40% to 80% of levodopa is released after 3 hours;

60% to 100% of levodopa is release after 4 hours; and

~~and~~ not less than 80% is released after 7 hours.

57. The use ~~method~~ of claim 1, wherein after administration the controlled release dosage form provides ~~produces~~ a levodopa plasma level of at least 300 ng/mL within 0.25 to 1 hour after administration.

68. The use ~~method~~ of claim 1 wherein after twice a day administration of the controlled release dosage form ~~about every twelve hours~~ for at least 7 days provides a ~~the~~ minimum levodopa plasma level at least ~~is about~~ 250 ng/mL six ~~seven~~ to eight hours after dosing.

79. The use ~~method~~ of claim 2~~4~~, wherein after administration of the controlled release dosage form twice a day ~~about every twelve hours~~ for at least 7 days, the minimum carbidopa plasma level is ~~about~~ at least 40 ng/mL seven to eight hours after dosing.

810. The use ~~method~~ of claim 1, wherein the patient is ~~a~~ newly diagnosed with Parkinson's disease ~~or is a levodopa naive patient~~.

9. The use of claim 1, wherein the patient exhibits a decrease of at least 10% of the patient's total post dose "Off" time as compared to post dose of a comparable oral dose of an immediate release dosage form comprising levodopa or an ester or a salt thereof, or the total oral immediate release doses per day or per waking hours.

1011. The use of claim 9, ~~A method for treating a patient diagnosed with Parkinson's disease comprising the oral administration of a controlled release dosage form comprising levodopa and a controlled release excipient and/or a muco-adhesive excipient; the administration of the controlled release dosage form occurs every twelve hours or every seven to eight hours and~~ wherein the patient exhibits: ~~(i)~~ a total "Off" time during in a 24 hour period and/or during waking hours in a 24 hour period

of less than 5 hours~~; (ii) a total "Off" time during waking hours of less than 5 hours in a 24 hour period; (iii) a total On time of more than 5 hours during the dosing time interval; (iv) a total Good On time of more than 5 hours during the dosing time interval; (v) an increase of at least 20 minutes of the patient's "On" time per day compared to total comparable oral immediate release CD-LD doses per day; (vi) an increase of at least 20, minutes of the patient's "Good On" time per day compared to total comparable oral immediate release CD-LD doses per day; or (vii) a combination of the foregoing~~.

11. The use of claim 1, wherein the patient exhibits a total post dose “On” time and/or a total post dose “Good On” time of 5 hours or more during a 24 hour period and/or or during waking hours in a 24 hour period.

12. The use of claim 1, wherein the patient exhibits an increase of at least 20 minutes of the patient's total post dose "On" time and/or a total post dose “Good On” time per dose, per day and/or during waking hours per day compared to post dose of a comparable oral immediate release levodopa or ester or salt thereof dose per day and/or during waking hours in a 24 hour period.

~~12. The method of claim 11 wherein the controlled release dosage form comprises one or more capsules comprising:~~

~~(a) 140 mg of levodopa and 35 mg of carbidopa;~~

~~(b) 210 mg of levodopa and 52.5 mg of carbidopa;~~

~~(c) 280 mg of levodopa and 70 mg of carbidopa;~~

~~(d) 350 mg of levodopa and 87.5 mg of carbidopa; or~~

~~(e) a combination of the foregoing.~~

~~13. A method for treating a patient diagnosed with Parkinson’s disease comprising the oral administration of a controlled release dosage form comprising levodopa and a controlled release excipient and/or a muco-adhesive excipient; the administration of the controlled release dosage form occurs every twelve hours or every seven to eight hours and the patient exhibits at least a 5% reduction in total "Off" time during waking hours compared to the patient receiving treatment with an immediate release levodopa and carbidopa oral dosage form.~~

~~14. The method of claim 13 wherein the controlled release dosage form comprises one or more capsules comprising:~~

~~(a) 140 mg of levodopa and 35 mg of carbidopa;~~

~~(b) 210 mg of levodopa and 52.5 mg of carbidopa;~~

~~(c) 280 mg of levodopa and 70 mg of carbidopa;~~

~~(d) 350 mg of levodopa and 87.5 mg of carbidopa; or~~

~~(e) a combination of the foregoing.~~

~~15. A method for treating a patient diagnosed with Parkinson's diseasecomprising the oral administration of a controlled release dosage form comprising levodopa and a controlled release excipient and/or a muco-adhesive excipient; the administration of the controlled release dosage form occurs every twelve hours or every seven to eight hours and the patient exhibits a total "Off" time during the dosing interval of 180 minutes or less.~~

~~16. The method of claim 15 wherein the controlled release dosage form comprises one or more capsules comprising:~~

~~(a) 140 mg of levodopa and 35 mg of carbidopa;~~

~~(b) 210 mg of levodopa and 52.5 mg of carbidopa;~~

~~(c) 280 mg of levodopa and 70 mg of carbidopa;~~

~~(d) 350 mg of levodopa and 87.5 mg of carbidopa; or~~

~~(e) a combination of the foregoing.~~

~~17. A method for treating a patient diagnosed with Parkinson's disease comprising the oral administration of a controlled release dosage form comprising levodopa and a controlled release excipient and/or a muco-adhesive excipient; the administration of the controlled release dosage form occurs every twelve hours or every seven to eight hours and the patient is administered the controlled release dosage form about 30 minutes or less before bedtime and the PD patient will wake about 7 to about 8 in an On or Good On state.~~

~~18. The method of claim 17 wherein the controlled release dosage form comprises one or more capsules comprising:~~

~~(a) 140 mg of levodopa and 35 mg of carbidopa;~~

(b) 210 mg of levodopa and 52.5 mg of carbidopa;

(c) 280 mg of levodopa and 70 mg of carbidopa;

(d) 350 mg of levodopa and 87.5 mg of carbidopa; or

(e) a combination of the foregoing.

19. A method for treating a patient diagnosed with Parkinson's disease comprising the oral administration of a controlled release dosage form comprising levodopa and a controlled release excipient and/or a muco-adhesive excipient; the administration of the controlled release dosage form occurs every twelve hours or every seven to eight hours and the patient is administered the same dose at each dosing interval.

20. The method of claim 19 wherein the controlled release dosage form comprises one or more capsules comprising:

(d) 140 mg of levodopa and 35 mg of carbidopa;

(e) 210 mg of levodopa and 52.5 mg of carbidopa;

(f) 280 mg of levodopa and 70 mg of carbidopa;

(d) 350 mg of levodopa and 87.5 mg of carbidopa; or

(e) a combination of the foregoing.

21. A method for treating a patient diagnosed with Parkinson's disease comprising the oral administration of a controlled release dosage form comprising levodopa and a controlled release excipient and/or a muco-adhesive excipient; the administration of the controlled release dosage form occurs every twelve hours or every seven to eight hours and the patient is administered the controlled release dosage form under fed or fasting conditions and the patient exhibits a similar or increased levodopa maximum plasma concentration (C_{max}) and/or levodopa area under the plasma concentration time curve (AUC) when the controlled release dosage form is administered under fed conditions compared to administration under fasting conditions.

22. The method of claim 21 wherein the controlled release dosage form comprises one or more capsules comprising:

(g) 140 mg of levodopa and 35 mg of carbidopa;

(h) 210 mg of levodopa and 52.5 mg of carbidopa;

(i) 280 mg of levodopa and 70 mg of carbidopa;

~~(d) 350 mg of levodopa and 87.5 mg of carbidopa; or~~

~~(e) a combination of the foregoing.~~

~~23. The method of claim 22 wherein the time to maximum levodopa plasma concentration ($T_{max\ levodopa}$) or the time to maximum carbidopa plasma concentration ($T_{max\ carbidopa}$) when the controlled release dosage form is administered under fed conditions is ± 5 hours of the $T_{max\ levodopa}$ Or $T_{max\ carbidopa}$ when the controlled release dosage form is to be administered under fasting conditions.~~

13. The use of claim 1, wherein the patient exhibits at least a 10% increase in the patient's post dose Patient Global Impression of Change (PGI-C) score compared to post dose of a comparable oral dose of an immediate release levodopa dosage form comprising levodopa or an ester or a salt thereof, or the total oral immediate release doses per day or per waking hours.

14. The use of claim 1, wherein the patient exhibits a total "Off" time of 240 minutes or less per dosing interval.

15. The use of claim 1, wherein a bedtime dose of the controlled release dosage form is to be administered to the patient 30 minutes or less before bedtime and the patient will wake in 6 to 9 hours after the bedtime dose in an "On" or "Good On" state.

16. The use of claim 1, wherein the methacrylate copolymer is a cationic dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate copolymer.

17. The use of claim 1, wherein the controlled release dosage form comprises:

(a) a plurality of controlled release components comprising a core comprising levodopa wherein the core is coated with a layer comprising the muco-adhesive excipient and externally coated with a layer comprising an enteric coating polymer; and

(b) an immediate release component comprising levodopa.

18. The use of claim 17, wherein the controlled release components (a) further comprise a rate-controlling polymer layer which undercoats the layer comprising the muco-adhesive excipient within the controlled release components.

19. The use of claim 17, wherein the controlled release components (a) are formulated as beads that passes through a 12, 14, and 16 mesh screen but are retained on 18, 20, or 24 mesh screen.